cells obtained from a glucose-limited chemostat died more rapidly in the presence of nalidixic acid than water-washed cells, which have a higher magnesium content. Indeed the death rate of the latter was the same in the presence and in the absence of drug, which confirms what has been said earlier about the effect of the growth rate on the activity of nalidixic acid. However this is not the complete picture since even when the growth medium contained a large excess of magnesium ions the growth rate in the presence of 65 mg/l of drug was only 0-6 h-' compared to a control value of 1 25 h-1. These investigations are proceeding.
Although the number of cases in Britain is steadily declining, tuberculosis in developing countries is probably the most important, in terms of numbers of patients and economic effects, of those communicable diseases for which some prospect of control and eventual prevention exists. Chemotherapy is necessary not only for treating ill patients, but also for preventing the transmission of infection to the contacts of patients. We can only hope to reduce the prevalence of tuberculosis if such treatment has a high level of effectiveness.
Regimens of chemotherapy given in Britain are almost always effective when given to co-operative patients with initially drug-sensitive organisms. However, such regimens are far too expensive for use in most of the developing countries.
Low Cost Regimens of Thiacetazone and Isoniazid A series of studies in East Africa has shown that a basic regimen of isoniazid and thiacetazone is similar in efficacy and toxicity to a regimen of PAS and isoniazid, but about ten times cheaper. However, these two-drug regimens produce bacteriologically quiescent disease in only about 85 % of patients. Since regimens commencing with a period of triple-drug treatment have high levels of efficacy (International Union against Tuberculosis 1964), the influence of an initial supplement of streptomycin to the basic thiacetazone/isoniazid regimen was investigated in two trials (East African/British Medical Research Council 1966 , 1970b . In both, African patients aged 15 years or more with previously untreated, acute, extensive pulmonary tuberculosis were studied. In the 1966 study, patients were allocated thiacetazone 150 mg and isoniazid 300 mg daily (TH series) or the same regimen with an initial supplement of streptomycin 1 g daily for 8 weeks (STH series). The severity of the disease on admission to treatment was similar in the two series. In assessing the results (Table 1) , patients with a negative culture at 10, 11 and 12 months or, occasionally, with a single isolated positive culture were classified as having a favourable response at 12 months. Those who consistently yielded positive cultures, who died from tuberculosis or who had serious drug toxicity were considered as having an unfavourable response.
A favourable response was obtained in 79 % of 181 TH patients and in 90% of 162 STH patients (P <0 01). Isoniazid resistance also emerged less frequently in the STH than in the TH series. The results of sensitivity tests and serial urine tests for isoniazid in the STH series suggested that, for the majority of those patients whose chemotherapy failed, the cause of failure was irregular drugtaking during the later months of treatment. The results of the 1966 study clearly demonstrated that an initial supplement of streptomycin greatly improved the basic thiacetazone/isoniazid regimen. Such a supplement is not, however, given in many East African centres since hospital beds are not available for the initial period and, even when such beds are available, they would add greatly to the costs. The 1970 study was therefore undertaken to explore the duration of the initial streptomycin supplement. The patients were allocated at random to 4 regimens in which the basic thiacetazone/isoniazid regimen was supplemented with streptomycin 1 g daily for 8 (S8 series), 4 (S4 series) or 2 weeks (S2 series) or in which no initial supplement was given (TH series). The results of treatment for 1 year are shown in Table 2 . As the duration of treatment with streptomycin was increased theeffectiveness of the regimen became progressively greater. These results suggest that initial streptomycin treatment for at least 4 weeks, and preferably 8 weeks, should be given.
Comparison ofResults in a Trial and in Routine Practice
Immedately after the 1966 trial, a survey of the prevalence of drug-resistant tubercle bacilli in the sputum of a random sample of patients was undertaken in Kenya (East African/British Medical Research Council 1968). A second specimen of sputum was obtained from the patients one year later. No attempt was made to influence the treatment or the follow up of the patients in the intervening year, so that the results of cultures of the second sputum specimen give an estimate of the efficacy oftreatment in the routine tuberculosis service in Kenya (East African/British Medical Research Council 1970a). A comparison could now be made between the results of treatment in the 1966 trial, when particular efforts were made to follow up the patients, and in a comparable group of patients treated under routine conditions in the survey (Kent et al. 1970) .
In order to make the comparison valid, a considerable proportion of patients had to be Table 3 , according to the treatment given to the patients. Considering the TH patients, those treated in the trial did slightly better than those treated in the survey, the difference being largely due to an excess of deaths (usually from tuberculosis) in the survey series. Considering next the STH patients, those in the trial fared substantially better than those in the survey. Indeed, although the evidence of the benefit of the initial streptomycin supplement in the trial patients was very strong, a more detailed examination of the survey results failed to show any evidence of benefit due to streptomycin in routine treatment. The probable explanation for this unexpected finding is that the good effects of the initial treatment with streptomycin were undone in routine practice by greater irregularity in drug taking and early cessation of treatment. In the survey patients, the duration of treatment with thiacetazone/isoniazid was of overwhelning prognostic importance; those who stopped their treatment early did badly while those who continued for the full year did well. These results indicate that taking drugs regularly for at least a year is of much greater importance than the use of the most efficient regimen of treatment.
Intermittent Chemotherapy
One way in which the patients might be encouraged to maintain their drug-taking during the later months of treatment is to give the drugs at Section ofExperimental Medicine & Therapeutics with Section of Pathology 539 intervals of several days, supervised by a responsible person, usually a member of the staff of a medical clinic. Supervised intermittent chemotherapy has the following advantages: (1) The dosage of drugs actually taken by the patient is accurately known.
(2) Immediate steps can be taken to locate a patient who fails to attend for a supervised dose.
(3) There is frequent, regular contact with the clinic staff which should encourage co-operation. (4) The cost of drugs is usually reduced. Treatment with twice-weekly high dosage isoniazid and streptomycin has been shown to be an effective form of chemotherapy even when prescribed from the start of treatment (Tuberculosis Chemotherapy Centre, Madras 1964 , Ramakrishnan et al. 1969 ). Large scale trials in which a short period of conventional daily chemotherapy is followed by twice-weekly intermittent treatment are being undertaken by the International Union against Tuberculosis and in Czechoslovakia and Britain. Preliminary results indicate the high efficacy of the regimens. However, patients in the rural populations common in developing countries, find it difficult to travel to a clinic as often as twice a week. The development of effective once-weekly regimens would thus open great opportunities for the extended use of fully supervised intermittent regimens. Table 4 shows the dosages of drugs used in a recent study at the Tuberculosis Chemotherapy Centre, Madras (1970) , in which a twice-weekly regimen of high dosage isoniazid and streptomycin (SHTW) was compared with three regimens in which the same doses of isoniazid and streptomycin were administered once weekly. The basic once-weekly regimen (SHOW) was strengthened either by the addition of pyrazinamide in a high dose of 90 mg/kg given once weekly with the other drugs (SHZOW) or by giving 4 weeks of daily isoniazid and streptomycin preceding the once-weekly basic regimen (SH/ SHOW). Throughout the study patients received 1 g or 0-75 g streptomycin and were also classified as slow or rapid inactivators of isoniazid. These regimens were given to previously untreated patients with drug-sensitive organisms. The results are summarized in Table 5 . The SHTW regimen had a high level of efficacy, similar in slow and rapid inactivators of isoniazid and in patients receiving the high or low dosage of streptomycin. However, the regimens with once-weekly intermittent dosage were less effective. In all three series, the response to treatment was substantially less good in rapid inactivators than in slow inactivators of isoniazid. Giving a preliminary 4 weeks of daily treatment in the SH/SHOW series greatly improved the results and it is particularly noteworthy that the response of slow inactivators of isoniazid was as good as in the SHTW series. From this finding and from a second study (unpublished) with similar results, one can conclude that if the SH/SHOW regimen were used for treating slow inactivators only, we would already have an efficient once-weekly form of treatment. A current line of investigation is to explore the use of delayed absorption preparations of isoniazid which could produce serum concentrations of the drug in rapid inactivators equivalent to those found in slow inactivators following administration of an ordinary preparation of the drug. In addition, there is experimental evidence to suggest that the newer antituberculous drugs, ethambutol and rifampicin, might be effective when given intermittently (Dickinson et al. 1968 , Dickinson & Mitchison 1970 . A recent French study indicates that daily and twice-weekly regimens of rifampicin and isoniazid are of equal efficacy (Decroix et al. 1969 ).
Reduction in Duration ofTreatment
A second possible solution to the problem of patient co-operation is to develop regimens which would be effective if given for a shorter total duration than at present. Since the rate of sputum conversion in patients treated-with a rifampicin/ isoniazid regimen is more rapid than with a streptomycin/isoniazid regimen (Dormer 1969) and because high dosage of rifampicin is remarkably effective in sterilizing the organs of mice (Grumbach 1969 , Batten 1969 , there is a possibility that the relapse rate folowing relatively short courses of treatment with rifampicincontaining regimens might be lower than has been obtained with other drugs. This possibility is under current study in East Africa. This paper describes preliminary work designed to assess the biological significance of mercury resistance as a factor i the survival ability of staphylococci within the antibiotic-laden hospital environment.
Relationship ofMercury Resistance to Multiple Antibiotic Resistance
This survey was carried out on the 256 epidemiologically distinct strains of tetracycline-resistant staphylocci described previously (Wliams 1967); it was confined to tetracycline-resistant strains because: (1) The term multiple-resistance in staphylococci indudes tetracycline resistance.
(2) Naturally-occurrng penicillin resistance is now an extremely common feature of staphylococci. As strains that are resistant to penicillin 'Preont addres: Monsall Hospital, Newton Heath, Manchester 10 only are y mercury-senstive, their inclusion would have the survey heavily in favour of moc y sitivity.
The sutains were ali tested with Mastinp carrying a standard group of antibiotics: benzylpenicilin (P) 4 unit;s (8S) 25 mg; tetracycine (1) 50 g; chiormpmicol (C) 50 pg; erythromycin (E) 5 pg; neomycin (N) 30 pg; novobiocim (Nv) 5 p Methicillin (Cl) sensitivity was tested separately on salt-ar plates with discs (Mast) impregnated with 10 pg cloxacillin (Churcher 1968). In the later experiments detaie in this paper strains were also tested with discs impregnated with 10 pg of fusidic acid (F).
These 8 ant tib s (not incluing fusidic acid) were used because they are the ones to which staphylococci have been most subjected for a nwnber of years, and buse the majority of them serve as useftul makers of staphylococcal behaviour. greater propensity for developing multiple resistance; the relationships between mercury resistance and high penicillinase activity, multiple
